Navigation Links
Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
Date:10/20/2009

BALTIMORE, Oct. 20 /PRNewswire/ -- Celsis International is pleased to announce that the United States Patent and Trademark Office today issued U.S. Patent No. 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). This patent generally covers processes by which the company creates its unique LiverPool(TM) products for drug discovery research. The pooling process combines primary cells from multiple donors to create large lots with targeted activity levels. The resulting LiverPool product is flexible, customizable and repeatable, enabling scientists to run multiple studies on various compounds or NCEs anywhere in the world, and at any time, which speeds up decision making and reduces the time and cost of drug research.

"Our LiverPool product is a great example of Celsis IVT's pioneering work in developing ADME-Tox products that meet the research needs of our customers, while helping to take costs out of the drug discovery process," said Judy Madden, vice president of strategic development for Celsis. "We're proud that the US Patent Office has recognized our continued innovation and awarded us this patent."

Celsis IVT has been producing LiverPool products for more than five years and they have been incorporated into the standard research protocols of major pharmaceutical companies around the world. Research conducted with LiverPool has documented its efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies. Scientific posters and LiverPool product information are available online at www.celsis.com/liverpool.

About Celsis IVT

Celsis IVT is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for q
'/>"/>

SOURCE Celsis International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chicago-Based Celsis International Goes Private
2. Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes
3. Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
4. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
5. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
6. Celsis Receives Frost & Sullivan 2008 Best Practices Award
7. Peripheral Artery Disease (PAD) Patent Granted to Dimera
8. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
9. Delcath Systems Granted Third Orphan Drug Designation
10. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
11. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... and NEW YORK , ... from its open-label pilot study of mazindol in children ... Development and Therapy in December 2014 . ... mazindol in children with attention deficit/hyperactivity disorder" ( Konofal ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Adjusted Earnings and Backlog Increase to Record Highs, ... ), a diversified medical technologies company specializing in,diagnostics, imaging ... of women, today announced its results for the,quarter ended ... include:, -- Record revenues of $371.4 million. ...
... Product Candidate Trop-2 Signal ... Transduction Antibody -, ... full-,service biopharmaceutical development and protein production company, today,announced that it ... Inc., a biotechnology company focused on discovering,and developing the next ...
... Jan. 31 /PRNewswire-FirstCall/ - ARIUS Research Inc., ... the next wave of,antibody therapeutics, today announced ... manufacturing agreement for its Trop-2 Signal Transduction,Antibody ... and protein production company located in Princeton, ...
Cached Biology Technology:Hologic Announces First Quarter Fiscal 2008 Operating Results 2Hologic Announces First Quarter Fiscal 2008 Operating Results 3Hologic Announces First Quarter Fiscal 2008 Operating Results 4Hologic Announces First Quarter Fiscal 2008 Operating Results 5Hologic Announces First Quarter Fiscal 2008 Operating Results 6Hologic Announces First Quarter Fiscal 2008 Operating Results 7Hologic Announces First Quarter Fiscal 2008 Operating Results 8Hologic Announces First Quarter Fiscal 2008 Operating Results 9Hologic Announces First Quarter Fiscal 2008 Operating Results 10Hologic Announces First Quarter Fiscal 2008 Operating Results 11Hologic Announces First Quarter Fiscal 2008 Operating Results 12Hologic Announces First Quarter Fiscal 2008 Operating Results 13Hologic Announces First Quarter Fiscal 2008 Operating Results 14Hologic Announces First Quarter Fiscal 2008 Operating Results 15Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 2Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 3ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 2ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 3ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody 4
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season ... industry as Acuity Market Intelligence reports that the ... be open. Acuity forecasts that intensifying demand for ... incorporate biometrics will drive a global market of ... devices by 2020.   According to ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... conservation successes in the face of rapid environmental change ... adapt to local climate. To improve scientists, understanding ... 2011 issue of Science helps define the ... The National Science Foundation partly funded the study, which ...
... and technologies from more than 850 scientific, technical and ... 95th Annual Meeting, Frontiers in Optics (FiO) 2011, being held ... Sainte Claire hotels in San Jose, Calif. Held in conjunction ... Physical Society (APS) Division of Laser Science (DLS), the meeting ...
... The scope and intensity of mercury pollution in ... reported, but additional mercury controls should bring needed improvement, ... the subject. Despite general declines in mercury levels ... decades, mercury concentrations still exceed human and ecological risk ...
Cached Biology News:Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 2Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 3Optics innovations to be showcased during OSA's Annual Meeting, Frontiers in Optics 2011 4Mercury pollution in the Great Lakes region -- nearly forgotten, but not gone 2Mercury pollution in the Great Lakes region -- nearly forgotten, but not gone 3
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... is specifically designed to target and display ... cerevisiae. Displayed proteins can be analyzed for ... putative ligands. pYD1 uses the a-agglutinin yeast ... Aga1 and Aga2 to display recombinant protein ...
... S is a member of a class of ... the DNA sequence. Mut S plays an integral ... ,replication, in transcription-coupled nucleotide excision repair and in ... Mut S binds to DNA specifically at base ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: